An artificial intelligence (AI) program that aims to make it easier to identify bone metastases in men with prostate cancer has been granted 501(k) clearance by the U.S. Food and Drug Administration (FDA), its developer announced. The program uses a neural network — a type of AI — to identify hotspots on bone scans indicative of bone…
ImmunoGen has announced a collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co, a subsidiary of Huadong Medicine, to develop and commercialize the ovarian cancer treatment mirvetuximab soravtansine to patients in China, Hong Kong, Macau, and Taiwan. The partnership will combine ImmunoGen’s expertise in cancer medication development with Huadong Medicine’s familiarity with regulatory agencies and connections to…
Janssen is seeking to extend approval of its under-the-skin formulation of Darzalex (daratumumab) to include its use in combination with Pomalyst (pomalidomide) and dexamethasone to treat relapsed or refractory multiple myeloma patients who received at least one prior line of therapy. The company submitted applications for this combination therapy to regulatory agencies in the U.S. and the European Union. Darzalex…
Myeloma UK is calling for more data transparency in government efforts to safeguard myeloma patients during the COVID-19 pandemic. This comes after results were released from its COVID-19 survey that sought to examine the rate of COVID-19 infection among myeloma patients, changes to planned treatment due to the viral outbreak, and how the unfolding pandemic…
ALLO-715, an investigational donor-derived CAR T-cell therapy by Allogene Therapeutics, has a manageable safety profile and promising preliminary efficacy results in people with relapsed or refractory multiple myeloma, a Phase 1 clinical trial has shown. The results will be presented at the 62nd Annual Meeting of the American Society of Hematology, taking place virtually in…
First-line treatment with a combination of Keytruda (pembrolizumab) plus chemotherapy significantly prolongs survival, and extends life without disease progression, in people with advanced non-squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 status, results from a Phase 1/2 trial show. Compared with platinum-based chemotherapy alone, the combo treatment also led to higher response rates in…
Enrollment has resumed in a five-year U.K. study investigating genetic factors behind the higher risk of prostate cancer in men of African and Caribbean descent. The study involves researchers at The Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust, in London, who will run initial biopsy and genetic profiling tests. Black men…
A blood test measuring levels of the protein cancer antigen 125 (CA125) can help detect ovarian cancer in a primary care setting with considerable accuracy, a study reported. The research also showed for a first time that this test can also help in identifying other cancer types, particularly in women ages 50 and older. The…
Administering radiation therapy to people with relapsed or refractory (resistant) multiple myeloma waiting for CAR T-cells to be manufactured was found to be safe and did not impact CAR T-cell therapy, a small study reports. The study details were shared at the virtual 2020 American Society for Radiation Oncology (ASTRO) Annual Meeting, in a presentation…
The sugars that breast cancer cells shed into the bloodstream could provide an early cancer warning, according to a press release from GlycoNet, Canada’s national network of sugar science researchers. Karla Williams, PhD, Canada research chair in oncology at the University of British Columbia, discovered that certain glycans — long chains of sugars — are…
